Polyphor reinvents itself after abandoning antibiotic trial
Polyphor's prospects and its share price plunged this year when it halted a trial of its intravenous murepavadin antibiotic…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.